A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of Poly ADP-Ribose Polymerase-1 (PARP)

Clinical trial NCT00516373 · COMPLETED

Trial details

NCT number: NCT00516373
Sponsor: AstraZeneca
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Ovarian Neoplasms BRCA1 Protein BRCA2 Protein

Start date: 2005-07-11
Primary completion: 2008-12-17
Enrollment: 98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.